PDCD1 and metastatic melanoma: Anti-PD1 and anti-CTLA-4 antibodies have significantly increased the survival of patients with advanced cancers, such as metastatic melanoma, whose 5-year survival in 2009 was around 10% [4], while today, it is possible to achieve a 5-year survival of 52% [5].